AQW051

TargetMol
Product Code: TAR-T26646
Supplier: TargetMol
CodeSizePrice
TAR-T26646-1mg1mg£98.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26646-1mL1 mL * 10 mM (in DMSO)£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26646-5mg5mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26646-10mg10mg£182.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26646-25mg25mg£303.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26646-50mg50mg£436.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26646-100mg100mg£610.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26646-500mg500mg£1,219.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
AQW051 is a potent and selective partial agonist of α7 nicotinic ACh receptor.
CAS:
669770-29-0
Formula:
C19H22N2O
Molecular Weight:
294.398
Pathway:
Neuroscience
Purity:
0.98
SMILES:
Cc1ccc(cc1)-c1ccc(O[C@H]2CN3CCC2CC3)cn1
Target:
AChR

References

1. Barch DM, Marder SR, Harms MP, Jarskog LF, Buchanan RW, Cronenwett W, Chen LS, Weiss M, Maguire RP, Pezous N, Feuerbach D, Lopez-Lopez C, Johns DR, Behrje RB, Gomez-Mancilla B. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3;71:66-75. doi: 10.1016/j.pnpbp.2016.06.013. PubMed PMID: 27371157. 2. Welsh KJ, Bai Y; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists.. Pathology Consultation on Patients With a Large Rh Immune Globulin Dose Requirement. Am J Clin Pathol. 2016 Jun;145(6):744-51. doi: 10.1093/ajcp/aqw051. Review. PubMed PMID: 27267375. 3. Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569. PubMed PMID: 26990766. 4. Beinat C, Banister SD, Herrera M, Law V, Kassiou M. The therapeutic potential of ?7 nicotinic acetylcholine receptor (?7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs. 2015 Jul;29(7):529-42. doi: 10.1007/s40263-015-0260-0. Review. PubMed PMID: 26242477.